Video

Biopsy for Colorectal Cancer

When communicating with patients regarding the best options for colorectal cancer (CRC), it is important to emphasize the need for a biopsy to confirm the initial diagnosis and allow for genetic testing, notes Tanios Bekaii-Saab, MD. Genetic testing will not only improve the selection of frontline therapies but could also guide clinical trial eligibility. Fine needle aspiration may not capture enough cells to allow for proper testing, which could necessitate the patient undergoing a biopsy of the most accessible lesion, says Saab.

Patients should be informed of the risks associated with biospies but also reassured that a biopsy is performed under the guidance of a computed tomography scan or by ultrasound and carries a low risk of complications, notes Saab. Risks include bleeding and infection, which are rare. Pain is more common, but generally subsides after a few hours and can be managed with pain medications.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.